The purpose of this study is to test the safety and effects of a combination of a study drug,
Lapatinib, plus the administration of standard radiation therapy and an FDA approved drug
Temozolomide (chemotherapy agent) in patients with newly diagnozed glioblastoma
Multiforme.Currently, only radiation therapy and Temozolomide chemotherapy are standard
treatment for brain cancer.Lapatinib has not been FDA approved for use in brain tumors
treatment. It has been approved to be used as a daily treatment with other chemotherapies by
the FDA for the treatment of advanced breast cancer.
The purpose of this study is to find the answers to the following research questions:
1. Is Lapatinib given twice a week at higher dosages, with radiation therapy and
Temozolomide, safe when given to patients with brain tumor?
2. What are the side effects of Lapatinib given twice a week at higher dosages when given
with radiation therapy and Temozolomide and how often do they occur?
3. Can Lapatinib, radiation, and Temozolomide be effective in shrinking tumors when given
to patients with brain tumors?
4. To determine whether the presence of genetic alterations specific proteins in the tumor
samples can predict whether this study drug is effective on the tumor.